149 related articles for article (PubMed ID: 22202100)
1. Prophylactic vaccines for prevention of prostate cancer.
Naz RK; Shiley B
Front Biosci (Schol Ed); 2012 Jan; 4(3):932-40. PubMed ID: 22202100
[TBL] [Abstract][Full Text] [Related]
2. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
3. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer vaccines: current status and future potential.
Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
[TBL] [Abstract][Full Text] [Related]
5. Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines.
Todorova K; Zoubak S; Mincheff M; Kyurkchiev S
Anticancer Res; 2005; 25(6C):4727-32. PubMed ID: 16334167
[TBL] [Abstract][Full Text] [Related]
6. PSA-based vaccines for the treatment of prostate cancer.
Madan RA; Gulley JL; Arlen PM
Expert Rev Vaccines; 2006 Apr; 5(2):199-209. PubMed ID: 16608420
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen vaccines for prostate cancer.
Hörig H; Lee CS; Kaufman HL
Expert Opin Biol Ther; 2002 Apr; 2(4):395-408. PubMed ID: 11955277
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
9. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
Arlen PM; Gulley JL; Tsang KY; Schlom J
Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
11. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
12. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer vaccines in clinical trials.
Lubaroff DM
Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
[TBL] [Abstract][Full Text] [Related]
14. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.
Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A
Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
[TBL] [Abstract][Full Text] [Related]
16. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
[TBL] [Abstract][Full Text] [Related]
17. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses.
Ferraro B; Cisper NJ; Talbott KT; Philipson-Weiner L; Lucke CE; Khan AS; Sardesai NY; Weiner DB
Hum Vaccin; 2011; 7 Suppl():120-7. PubMed ID: 21266849
[TBL] [Abstract][Full Text] [Related]
20. Special report: vaccines for the treatment of prostate cancer.
Technol Eval Cent Assess Program Exec Summ; 2010 Apr; 24(6):1-2. PubMed ID: 20575182
[No Abstract] [Full Text] [Related]
[Next] [New Search]